Falsification of pharmaceuticals is an issue that affects us all because it risks public health and safety. Medicinal falsification threatens global health: as the level of sophistication of these products increases every year so does the risk of falsified medicines reaching the public. The importance of developing comprehensive prevention strategies in Europe, as well as the rest of the world, cannot be stressed enough.
The EU has set a new directive to protect medicinal products from falsification. These regulations will come into effect on 9th February 2019 under the delegated Act, EU 2016/161, which supplements the directive 2001/83/EC, the Falsified Medicines Directive (FMD).